Abstract
Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson’s disease (PD) related neuropathology and behavior deficits. This devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Numerous therapeutic strategies have been developed to protect neuronal damage, although no effective treatment for PD has been validated yet. This study tested the preventive and therapeutic neuroprotective effect of Atremorine on MPTP parkinsonian mouse model. In addition to behavioral analysis, nigrostriatal dopaminergic neurons and inflammation biomarkers were directly quantified in the affected brain regions by specific antibody-antigen-binding methods. The affected neuronal populations and behavioural alterations induced by MPTP were significantly impaired in mice when treated with Atremorine-rich diet. Differences in the Atremorine content in diet induced some degrees of neuropathological and behavior therapeutical improvement, based on the progressive beneficial effects observed in nigro-striatal dopaminergic neurons of MPTPinduced mice. Data demonstrated that Atremorine promotes neuroprotection and behavior recovery in the injured MTPT-mouse brain by modulating the expression levels of tyrosine hydroxylase, glial proteins, apoptosis and endogenous dopamine and neuromelanin concentrations, probably the key to recover the basal ganglia function.
Keywords: Parkinson's disease, MPTP, neuroinflammation, neuroprotection, biotherapy, inflammation biomarkers.
Current Pharmaceutical Design
Title:Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Volume: 23 Issue: 18
Author(s): Ivan Carrera*, Lucia Fernandez-Novoa, Carolina Sampedro and Ramon Cacabelos
Affiliation:
- Health Biotechnology, EuroEspes Biotechnology, 15165 – Corunna,Spain
Keywords: Parkinson's disease, MPTP, neuroinflammation, neuroprotection, biotherapy, inflammation biomarkers.
Abstract: Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson’s disease (PD) related neuropathology and behavior deficits. This devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Numerous therapeutic strategies have been developed to protect neuronal damage, although no effective treatment for PD has been validated yet. This study tested the preventive and therapeutic neuroprotective effect of Atremorine on MPTP parkinsonian mouse model. In addition to behavioral analysis, nigrostriatal dopaminergic neurons and inflammation biomarkers were directly quantified in the affected brain regions by specific antibody-antigen-binding methods. The affected neuronal populations and behavioural alterations induced by MPTP were significantly impaired in mice when treated with Atremorine-rich diet. Differences in the Atremorine content in diet induced some degrees of neuropathological and behavior therapeutical improvement, based on the progressive beneficial effects observed in nigro-striatal dopaminergic neurons of MPTPinduced mice. Data demonstrated that Atremorine promotes neuroprotection and behavior recovery in the injured MTPT-mouse brain by modulating the expression levels of tyrosine hydroxylase, glial proteins, apoptosis and endogenous dopamine and neuromelanin concentrations, probably the key to recover the basal ganglia function.
Export Options
About this article
Cite this article as:
Carrera Ivan*, Fernandez-Novoa Lucia, Sampedro Carolina and Cacabelos Ramon, Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170210143530
DOI https://dx.doi.org/10.2174/1381612823666170210143530 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Improving Health Care for Children with Chronic Conditions: Toward a “Wholistic” Approach
Current Pediatric Reviews Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease
Current Pharmaceutical Design Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Dopamine Signaling in Drug Addiction
Current Topics in Medicinal Chemistry Vitamin D: Preventive and Therapeutic Potential in Parkinson’s disease
Current Drug Metabolism Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry An Experimental Investigation of MLPNN and GRNN Classification Methods for Evaluation of Different sEMG-Extracted Features
Recent Patents on Computer Science Fluorinated Tropanes
Current Topics in Medicinal Chemistry Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research NMR Studies on How the Binding Complex of Polyisoprenol Recognition Sequence Peptides and Polyisoprenols Can Modulate Membrane Structure
Current Protein & Peptide Science Structural Bases for Substrate and Inhibitor Recognition by Matrix Metalloproteinases
Current Medicinal Chemistry The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target
Current Pharmaceutical Design Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer
Current Pharmaceutical Design Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
Current Cancer Drug Targets Editorial (Thematic Issue: Epigenetics and Neuro-behavioral Modulations)
Current Neuropharmacology